– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML –
– Multiple milestones and data readouts from KOMET-001 expected in 2022 –
Read more at globenewswire.comhello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
